¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"platelet activating factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • random donor platelet
    ¹«ÀÛÀ§ÇåÇ÷ÀÚÇ÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀÎÇåÇ÷ÀÚÇ÷¼ÒÆÇ, ÀÏÀΰøÇ÷ÀÚÇ÷¼ÒÆÇ
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÎÀÚ, Ç׎½ÄÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • antirachitic factor
    Ç×±¸·çº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ, ½É¹æ¼ÒµãÀÌ´¢ÀÎÀÚ
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet refractoriness
    Ç÷¼ÒÆÇºÒÀÀÈ­
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • random donor platelet
    ´ÙÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀΰøÇ÷Ç÷¼ÒÆÇ, ÀÏÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • antihemophlic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÛ¿ëÀÎÀÚ
  • antirachitic factor
    Ç×±¸·íº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • MPV => mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet
    Ç÷¼ÒÆÇ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet agitator
    Ç÷¼ÒÆÇÈ¥ÇÕ±â
  • platelet antibody
    Ç÷¼ÒÆÇÇ×ü(¡­ù÷ô÷).
  • platelet concentrate
    Ç÷¼ÒÆÇ³óÃà¾× (¡­ÒØõêäû).
  • platelet concentrates=PC
    ³óÃàÇ÷¼ÒÆÇ
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·(¡­Ï¡üñد).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • descending reticular activating system
    ÇÏÇ༺ ¸Á»óȰ¼º°è(ù»ú¼àõ ØÑßÒüÀàõͧ)
  • guanosine triphosphate-activating protein
    »ïÀλ걸¾Æ³ë½Å Ȱ¼º´Ü¹éÁú
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º °áÁ¤±â
  • reticular activating system
    ¸Á»óüȰ¼ºÈ­°è, ¸Á»óȰ¼º°è.
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • blood disc =b. platelet
    Ç÷¼ÒÆÇ(Ì´ËÛ̬).
  • blood platelet =thrombocyte
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • direct platelet count
    Á÷Á¢Ç÷¼ÒÆÇ°è»ê(¹ý)(?Ì´ËÛ̬˭Ë×ËÑ).
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
  • antianemia factor
    Ç׺óÇ÷ÀÎÀÚ(ù÷Þ¸úìì×í­)
  • antiberiberi factor
    Ç×°¢±âÀÎÀÚ(ù÷ÊÅѨì×í­)
  • antiblack-tongue factor
    Ç×Èæ¼³ÀÎÀÚ(ù÷ýÙàßì×í­)
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ(ù÷úìéÒÜ»ì×í­)
  • antihemophilic factor B
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) B
  • antihemophilic factor C
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) C
  • antineuritic factor
    Ç׽Ű漺ÀÎÀÚ(ù÷ãêÌèàõì×í­)
  • antinuclear factor
    Ç×ÇÙÀÎÀÚ(ù÷ú·ì×í­)
  • antipellagra factor
    Ç×(ù÷)Æç¶ó±×¶ó ÀÎÀÚ(ì×í­)
  • antipeptic ulcer factor
    Ç×(ù÷)±Ë¾ç(Ï÷åË) ÀÎÀÚ(ì×í­)
  • antipernicious anemia factor
    Ç×(ù÷)¾Ç¼ººóÇ÷(äÂàõÞ¸úì) ÀÎÀÚ(ì×í­)
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ(ù÷ÎÕúìÜ»ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PAF Platelet Activating Factor
PAF-A platelet-activating factor of anaphylaxis
PTAF platelet activating factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ATF1 Activating transcription factor 1
ATF2 Activating transcription factor 2
APAF-1 Apoptotic protease activating factor-1
ATF CRE)/activating transcription factor
LAF Lymphocyte Activating Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • attenuation factor
    °¨¾à ¿ä¼Ò, °¨¼è ¿äÀÎ
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • back scatter factor
    ÈÄ¹æ »ê¶õ °è¼ö
  • beam direction factor
    ¼±¼Ó ¹æÇâ ÀÎÀÚ
    ÀüÀÚÆÄ ¹æ»ç¼± ¶Ç´Â ÀÔÀÚ°¡ °°Àº ¹æÇâÀ¸·Î ¹æÃâÇÏ ´Â ¼Ó ¶Ç´Â ¼±ÀÇ ¹æÇâÀÇ ÀÎÀÚ.
  • behavioral factor
    Çൿ ¿äÀÎ
  • biological factor
    »ý¹°ÇÐÀû ¿äÀÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
amino acid activating enzyme <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate.
Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases.
(05 Mar 2000)
anionic neutrophil activating peptide <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
p53-activating kinase <enzyme> Regulates p53 activity in saccharomyces cerevisiae; 810 amino acid residues; genbank u24167; do not confuse with pak I, protease-activated kinase
Registry number: EC 2.7.10.-
Synonym: pak1 gene product, yeast pak1
(26 Jun 1999)
pantoate-activating enzyme pantothenate synthetase
virus activating protease <enzyme> Endoprotease from chick embryo; activates para- and orthomyoxovirus fusion glycoproteins by cleaving them at a single arginine site; ca(2+) dependent; similar to blood clotting factor x
Registry number: EC 3.4.21.-
(26 Jun 1999)
reticular activating system <physiology> A physiological term denoting that part of the brainstem reticular formation that plays a central role in the organism's bodily and behavorial alertness.
It extends as a diffusely organised neural apparatus through the central region of the brainstem into the subthalamus and the intralaminar nuclei of the thalamus; by its ascending connections it affects the function of the cerebral cortex in the sense of behavioural responsiveness; its descending (reticulospinal) connections transmit its activating influence upon bodily posture and reflex mechanisms (e.g., muscle tonus), in part by way of the gamma motor neurons.
See: reticular formation.
Synonym: non-specific system.
(05 Mar 2000)
GTPase activating protein <molecular biology> Originally purified as a 125 kD protein from bovine brain (1044 amino acids), stimulates the GTPase activity of ras p21 and thereby switches it to the inactive state.
GAP may itself be regulated by phospholipids and by phosphorylation on a tyrosine residue by growth factor receptors (PDGF R, EGF R). The neurofibromatosis type 1 gene NF1) codes for a protein homologous to GAP. GAP has both SH2 and SH3 domains. Another example is sar 1 (from yeast).
(18 Nov 1997)
methionine-activating enzyme <enzyme> An enzyme that catalyses the synthesis of s-adenosylmethionine from methionine and ATP.
Chemical name: ATP:L-methionine S-adenosyltransferase
Registry number: EC 2.5.1.6
(12 Dec 1998)
complement activating enzymes <enzyme> Enzymes present in the complement system which activate one or more components in the system.
Registry number: EC 3.-
(12 Dec 1998)
connective tissue activating peptide III Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
neutrophil activating protein <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
JNK-activating protein kinase <enzyme> A dual specificity kinase that activates jun kinases and p38-mpk2; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: jnk kinase, jnkk, hemipterous protein, hep protein, jun amino-terminal kinase kinase, jn kinase kinase, hep gene product
(26 Jun 1999)
acquired platelet function defect <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(29 Dec 1997)
antigens, human platelet Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
(12 Dec 1998)
anti-platelet agents Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á